BUSINESS Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy By Staff Monday, July 25, 2022 12:18 AM MISSION VIEJO, Calif.—Wellspring Ophthalmics, a development stage eyecare pharmaceutical company, announced that it has received its second patent for a novel cyclosporine dry eye therapy. This new patent and the company’s formulation platform strengthens the foundation for its entry into the global over $1.5 billion dry eye prescription eye drops market. “The addition of a second issued patent to our intellectual property portfolio adds more protection and value for the right development and commercialization partner to deliver an unmatched therapy to countless dry eye sufferers,” said Orlando Rodrigues, co-founder, CEO and president of Wellspring Ophthalmics, based here.“Based on the significant interest we’ve received to date, we are confident and enthused we will engage the right licensing partner near-term, so the work to bring this exciting dry eye innovation to market can continue,” Rodrigues said. Wellspring Ophthalmics said its flexible formulation platform overcomes known deficiencies of current cyclosporine eye drops because it is designed to have higher bioavailability for better efficacy and improved dry eye relief.